With a pioneer patent position and a portfolio of 29 issued and pending patents, InforMedix' IP is on a rock solid foundation for growth. InforMedix boasts a strong intellectual property portfolio that includes 15 issued and 14 pending patents. Most notably, the company owns the pioneer patents to technologies that provide dose-response data, a critical component to optimizing all clinical drug trials and disease management programs. In fact, the company's patents have been cited as prior art by patent examiners in over 150 other issued patents. InforMedix' patent claim protection falls into two categories. First are those that cover Med-eMonitor-like devices that contain medication containing compartments plus the patient alerting and monitoring keys and screen. Second are those that do not require the device to contain medication compartments. These claims are directed to the monitoring function and signaling of the patient, and extend into the realm of non-containment electronic diaries populated by Palm, iPaq and other PDA and PC entrants. Across these patents, the data communication may be by various means including telephone line, Internet data connection, wireless link or other interface with a communication port.